Phase 1/2 Study of Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors.

Trial Profile

Phase 1/2 Study of Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Cetuximab (Primary) ; Lenalidomide (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Dec 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2009-013423-31).
    • 25 Jul 2012 Status changed from recruiting to discontinued as reported by EudraCT.
    • 28 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top